Core Viewpoint - Elutia Inc. will release its third quarter 2025 financial results on November 6, 2025, after market close, followed by a conference call and webcast [1] Company Overview - Elutia develops and commercializes drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients [3] - The company focuses on humanizing medicine to ensure patients can thrive without compromise, addressing the growing need for implantable technologies [3]

Group 1 - Elutia Inc. will release its second quarter 2025 financial results after market close on August 14, 2025 [1] - A conference call and webcast will be hosted by the management team at 5:00 p.m. Eastern Time on the same day [1] - The conference call can be accessed by U.S. investors at 877-407-8029 and international investors at 201-689-8029, with a Conference ID of 13754773 [1] Group 2 - Elutia develops drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients [2] - The company focuses on addressing the needs of a growing population requiring implantable technologies [2] - Elutia's mission is to humanize medicine, allowing patients to thrive without compromise [2]